M&A Deal Summary |
|
|---|---|
| Date | 2016-05-03 |
| Target | Turing Pharmaceuticals - Intranasal Ketamine Program |
| Sector | Life Science |
| Buyer(s) | Adhera Therapeutics |
| Sellers(s) | Turing Pharmaceuticals |
| Deal Type | Divestiture |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1983 |
| Sector | Life Science |
| Revenue | 680K USD (2015) |
Adhera Therapeutics, Inc. is an oligonucleotide therapeutics company with broad drug discovery technologies providing the ability to develop proprietary single and double-stranded nucleic acid therapeutics including siRNAs, microRNA mimics, antagomirs, and antisense compounds, including messenger RNA therapeutics. These technologies were built via a roll-up strategy to discover and develop different types of nucleic acid therapeutics in order to modulate (up or down) a specific protein(s) which is either being produced too much or too little thereby causing a particular disease.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 2 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 2 |
| State: New York M&A | 1 of 1 |
| Country: United States M&A | 1 of 2 |
| Year: 2016 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-07-24 |
Symplmed Pharmaceuticals - DyrctAxess
Cincinnati, Ohio, United States Symplmed Pharmaceuticals, Inc. - DyrctAxess offers enhanced efficiency, control and information to empower patients, physicians and manufacturers to help achieve optimal care. |
Buy | - |
Turing Pharmaceuticals LLC is a privately-held biopharmaceutical company with offices in New York City and Zug, Switzerland. Turing focuses on developing and commercializing innovative treatments for serious diseases and conditions across a broad range of therapeutic areas, for which there are currently limited or no treatment options. Products being developed include intranasal ketamine for a variety of mood disorders and Syntocinon® (oxytocin nasal solution) for multiple indications. Vecamyl® (mecamylamine HCl tablets) for hypertension is Turing’s first commercial product.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: New York M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2016 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-08-10 |
Impax Laboratories - Daraprim
Hayward, California, United States Impax Laboratories - Daraprim is indicated for the treatment of toxoplasmosis in combination with a sulfonamide. The most common side effects that may occur with Daraprim include allergic reactions, blood disorders, tongue changes, blood in the urine, heart rhythm disorders, anorexia, and vomiting. |
Buy | - |
